FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4288425344> ?p ?o ?g. }

• W4288425344 endingPage "110" @default.
• W4288425344 startingPage "102" @default.
• W4288425344 abstract "Gemcitabine/cisplatin (GC) combination therapy has been the standard palliative chemotherapy for patients with advanced biliary tract cancer (BTC). No randomized clinical trials have been able to demonstrate the survival benefit over GC during the past decade. In our previous phase II trial, adding S-1 to GC (GCS) showed promising efficacy and we aimed to determine whether GCS could improve overall survival compared with GC for patients with advanced BTC.We performed a mulitcenter, randomized phase III trial across 39 centers. Enrolled patients were randomly allocated (1:1) to either the GCS or GC arm. The GCS regimen comprised gemcitabine (1000 mg/m2 ) and cisplatin (25 mg/m2 ) infusion on day 1 and 80 mg/m2 of S-1 on days 1-7 every 2 weeks. The primary endpoint was overall survival (OS) and the secondary endpoints were progression-free survival (PFS), response rate (RR), and adverse events (AEs). This study is registered with Clinical trial identification: NCT02182778.Between July 2014 and February 2016, 246 patients were enrolled. The median OS and 1-year OS rate were 13.5 months and 59.4% in the GCS arm and 12.6 months and 53.7% in the GC arm, respectively (hazard ratio [HR] 0.79, 90% confidence interval [CI]: 0.628-0.996; P = .046 [stratified log-rank test]). Median PFS was 7.4 months in the GCS arm and 5.5 months in the GC arm (HR 0.75, 95% CI: 0.577-0.970; P = .015). RR was 41.5% in the GCS arm and 15.0% in the GC arm. Grade 3 or worse AEs did not show significant differences between the two arms.GCS is the first regimen which demonstrated survival benefits as well as higher RR over GC in a randomized phase III trial and could be the new first-line standard chemotherapy for advanced BTC. To exploit the advantage of its high RR, GCS is now tested in the neoadjuvant setting in a randomized phase III trial for potentially resectable BTC." @default.
• W4288425344 created "2022-07-29" @default.
• W4288425344 creator A5004189669 @default.
• W4288425344 creator A5010659470 @default.
• W4288425344 creator A5013781849 @default.
• W4288425344 creator A5015679349 @default.
• W4288425344 creator A5016814013 @default.
• W4288425344 creator A5019626901 @default.
• W4288425344 creator A5024088812 @default.
• W4288425344 creator A5026988448 @default.
• W4288425344 creator A5035027513 @default.
• W4288425344 creator A5038916352 @default.
• W4288425344 creator A5040676201 @default.
• W4288425344 creator A5040778839 @default.
• W4288425344 creator A5044214575 @default.
• W4288425344 creator A5053879423 @default.
• W4288425344 creator A5056173852 @default.
• W4288425344 creator A5073275097 @default.
• W4288425344 creator A5073472318 @default.
• W4288425344 creator A5075280177 @default.
• W4288425344 creator A5086522106 @default.
• W4288425344 creator A5088537381 @default.
• W4288425344 creator A5090555589 @default.
• W4288425344 date "2022-08-09" @default.
• W4288425344 modified "2023-10-17" @default.
• W4288425344 title "Randomized phase <scp>III</scp> study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer ( <scp>KHBO1401</scp> ‐ <scp>MITSUBA</scp> )" @default.
• W4288425344 cites W1989877017 @default.
• W4288425344 cites W2019607817 @default.
• W4288425344 cites W2023201628 @default.
• W4288425344 cites W2025769688 @default.
• W4288425344 cites W2040872961 @default.
• W4288425344 cites W2051224942 @default.
• W4288425344 cites W2055140790 @default.
• W4288425344 cites W2081994793 @default.
• W4288425344 cites W2087336559 @default.
• W4288425344 cites W2115261608 @default.
• W4288425344 cites W2121313610 @default.
• W4288425344 cites W2168106806 @default.
• W4288425344 cites W2321683347 @default.
• W4288425344 cites W2542452601 @default.
• W4288425344 cites W2553739594 @default.
• W4288425344 cites W2752583521 @default.
• W4288425344 cites W2916978683 @default.
• W4288425344 cites W2945391036 @default.
• W4288425344 cites W2977982707 @default.
• W4288425344 cites W3017215320 @default.
• W4288425344 cites W3031260765 @default.
• W4288425344 cites W3098982624 @default.
• W4288425344 cites W4288425344 @default.
• W4288425344 doi "https://doi.org/10.1002/jhbp.1219" @default.
• W4288425344 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35900311" @default.
• W4288425344 hasPublicationYear "2022" @default.
• W4288425344 type Work @default.
• W4288425344 citedByCount "50" @default.
• W4288425344 countsByYear W42884253442021 @default.
• W4288425344 countsByYear W42884253442022 @default.
• W4288425344 countsByYear W42884253442023 @default.
• W4288425344 crossrefType "journal-article" @default.
• W4288425344 hasAuthorship W4288425344A5004189669 @default.
• W4288425344 hasAuthorship W4288425344A5010659470 @default.
• W4288425344 hasAuthorship W4288425344A5013781849 @default.
• W4288425344 hasAuthorship W4288425344A5015679349 @default.
• W4288425344 hasAuthorship W4288425344A5016814013 @default.
• W4288425344 hasAuthorship W4288425344A5019626901 @default.
• W4288425344 hasAuthorship W4288425344A5024088812 @default.
• W4288425344 hasAuthorship W4288425344A5026988448 @default.
• W4288425344 hasAuthorship W4288425344A5035027513 @default.
• W4288425344 hasAuthorship W4288425344A5038916352 @default.
• W4288425344 hasAuthorship W4288425344A5040676201 @default.
• W4288425344 hasAuthorship W4288425344A5040778839 @default.
• W4288425344 hasAuthorship W4288425344A5044214575 @default.
• W4288425344 hasAuthorship W4288425344A5053879423 @default.
• W4288425344 hasAuthorship W4288425344A5056173852 @default.
• W4288425344 hasAuthorship W4288425344A5073275097 @default.
• W4288425344 hasAuthorship W4288425344A5073472318 @default.
• W4288425344 hasAuthorship W4288425344A5075280177 @default.
• W4288425344 hasAuthorship W4288425344A5086522106 @default.
• W4288425344 hasAuthorship W4288425344A5088537381 @default.
• W4288425344 hasAuthorship W4288425344A5090555589 @default.
• W4288425344 hasBestOaLocation W42884253441 @default.
• W4288425344 hasConcept C126322002 @default.
• W4288425344 hasConcept C126894567 @default.
• W4288425344 hasConcept C168563851 @default.
• W4288425344 hasConcept C197934379 @default.
• W4288425344 hasConcept C203092338 @default.
• W4288425344 hasConcept C207103383 @default.
• W4288425344 hasConcept C2776694085 @default.
• W4288425344 hasConcept C2778239845 @default.
• W4288425344 hasConcept C2780258809 @default.
• W4288425344 hasConcept C2781413609 @default.
• W4288425344 hasConcept C31760486 @default.
• W4288425344 hasConcept C44249647 @default.
• W4288425344 hasConcept C71924100 @default.
• W4288425344 hasConcept C90924648 @default.
• W4288425344 hasConceptScore W4288425344C126322002 @default.
• W4288425344 hasConceptScore W4288425344C126894567 @default.
• W4288425344 hasConceptScore W4288425344C168563851 @default.
• W4288425344 hasConceptScore W4288425344C197934379 @default.

• next